Vita Coco's Stock Is Still Too Expensive After The Pullback

About the Industry

Shares of Vita Coco Company, Inc. (NASDAQ: COCO - Get Free Report) were down 5.6% during trading on Wednesday after the company announced weaker than expected quarterly earnings. The company traded as low as $51.48 and last traded at $53.3570. Approximately 656,600 shares traded hands during mid-day trading, a decline of 8% from the average daily

Solid but less-than-perfect earnings weren't enough for this high-flying stock today.

Lower tariffs and higher prices are helping boost the company's margins.

The Vita Coco Company, Inc. (COCO) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for Vita Coco Company (COCO) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Vita Coco Company, Inc. (COCO) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.12 per share a year ago.

Full Year Net Sales were $610 million, up 18%, driven by strong Vita Coco Coconut Water growth of 26% Full Year Net Income Increased $15 million to $71 million and Non-GAAP Adjusted EBITDA 1 Increased $14 million to $98 million For Fiscal Year 2026, Expect Net Sales between $680 million and $700 million and Adjusted EBITDA 2 between $122 million and $128 million NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the fourth quarter and year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Compared to Prior Year Period Net sales were $128 million, up $0.5 million in the fourth quarter, resulting in full year net sales of $610 million, an increase of 18%.

Vita Coco Company, Inc. (NASDAQ: COCO - Get Free Report) has received an average rating of "Moderate Buy" from the eleven analysts that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price